Can a MALT1 blocker tame Hard-to-Treat lymphoma?

NCT ID NCT06622226

Terminated Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called ONO-7018 in people with relapsed or refractory Non-Hodgkin lymphoma. The drug works by blocking a protein called MALT1 that may help lymphoma cells grow. The study aims to see if the drug is safe and tolerable, and how it behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ONO-7018, a MALT1 inhibitor tablet taken by mouth
What this could lead to: If successful, this could lead to a new treatment option for people with Non-Hodgkin lymphoma that has not responded to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 2 participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Hiroshima Red Cross Hospital Atomic-bomb Survivors Hospital

Hiroshima, Hiroshima, Japan
Nagoya City University Hospital

Nagoya, Aichi-ken, Japan
National Hospital Organization Osaka National Hospital

Osaka, Osaka, Japan
National Hospital Organization Sendai Medical Center

Sendai, Miyagi, Japan
National Hospital Organization Shibukawa Medical Center

Shibukawa-shi, Gunma, Japan
The Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.